Nureca Reports Strong Q4 Growth, Expands Distribution, and Outlines Strategic Priorities for FY26 May 05, 2025
Nureca Limited's Q4 FY25 revenue increased by 87% to ₹317.50 crore, with EBITDA rising 156% to ₹32.00 crore. Full-year FY25 results show 19.3% revenue growth and 1,480.6% EBITDA growth. The company partnered with Swiggy for quick commerce expansion and completed FDA registration for its manufacturing facility. Strategic priorities for FY26 include manufacturing expansion, quick commerce leadership, product innovation, and export growth.
Nureca Expands Quick Commerce Reach: Dr Trust Products Now Available on Swiggy Instamart Apr 29, 2025
Nureca Secures Approval for New Manufacturing Facility in Punjab, Boosting 'Make in India' Initiative Apr 21, 2025
Nureca's Manufacturing Arm Secures US FDA Registration, Boosting Global Market Access Apr 12, 2025